Who
Samit Hirawat
Director
Company insider
Files Form 4 as: Director, Pacira BioSciences; EVP,Chief Med.Offr.,Drug Dev., Bristol-Myers Squibb.
In numbers
- Trades disclosed
- 92
- Buys
- 3
- Sells
- 0
- Bought
- $402K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Jul 2019
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —6,405 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,891 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,891 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —6,405 at $0.00 | filing |
| 27 Jan 2026filed 29 Jan 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —39,291 at $0.00 | filing |
| 27 Jan 2026filed 29 Jan 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —39,291 at $0.00 | filing |
| 25 Apr 2025filed 29 Apr 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Bought | $202K4,250 at $47.58 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,886 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,765 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,854 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —35,146 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —28,593 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —52,720 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —4,886 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —337 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $147K2,327 at $63.11 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —4,765 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —831 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $127K2,013 at $63.11 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —5,854 at $0.00 | filing |
News
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?BMY · fool.com · 20 Oct 2026Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should KnowBMY · aol.com · 16 Oct 2026Bristol Myers Squibb's Rally Has Momentum, but Can Its New Drugs Justify More Upside?BMY · insidermonkey.com · 16 Oct 2026
0 headlines in the last 90 days name Samit Hirawat; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.